NEHI and Prescriptions for a Healthy America convene on HIT policy best practices discussion
WASHINGTON — HIT policy needs to focus on specific goals for improving patient medication adherence in order to realize the goals of improving patient health and achieving cost savings in the U.S. healthcare system, according to an expert panel convened today by the Network for Excellence in Health Innovation and Prescriptions for a Healthy America.
In particular, the panel said the two highest priorities for HIT should be providing electronic access to accurate mediation lists and complete drug formulary information for prescribing physicians.
Just as important, according to the panel, users and patients should redouble efforts to win a realignment of payment priorities that will support utilization of numerous HIT capabilities that already exist but are lying dormant.
"There is room in HIT policy for specific priorities that will sharpen the focus on patient medication adherence,” stated NEHI executive director Valerie Fleishman. "But our panel also made clear that much can be done to exploit existing HIT capabilities and existing sources of data that are not being utilized for lack of payment support.”
The discussion took place Friday at “Connected Health, Better Adherence”, a roundtable at the Pew Conference Center in Washington hosted by NEHI, a national health policy institute, in partnership with Prescriptions for a Healthy America. The roundtable explored the potential of HIT to improve patient care, outcomes, safety and to lower costs through improved medication management and adherence. Speakers debated which innovations should be prioritized in technology adoption to meet the needs of all stakeholders.
BMS completes sale of global diabetes business to AstraZeneca
NEW YORK — Bristol-Myers Squibb Co. on Monday announced that it has completed the previously announced sale of its global diabetes business to AstraZeneca.
Bristol-Myers Squibb received from AstraZeneca a payment of approximately $2.7 billion in connection with the closing, and will receive by mid-February, a $600 million milestone payment from the recent U.S. approval of Farxiga (dapagliflozin). Under terms of the agreement, Bristol-Myers Squibb also will receive from AstraZeneca potential regulatory and sales-based milestone payments of up to $800 million, and royalty payments based on net sales through 2025.
In addition, AstraZeneca will make payments of up to $225 million if and when certain assets are subsequently transferred.
The transaction includes the rights to Bristol-Myers Squibb’s global diabetes business that was part of its collaboration with AstraZeneca, the former Amylin manufacturing facility in West Chester, Ohio, and also covers the future purchase by AstraZeneca of Bristol-Myers Squibb’s Mount Vernon, Indiana, manufacturing facility, no earlier than 18 months following the closing date.
GPhA outlines 2014 priorities
WASHINGTON — The Generic Pharmaceutical Association on Monday identified its key priorities for 2014 — guarding against confusion a proposed labeling change would cause; gaining access to biosimilar generics; and heralding the cost savings generated by generic utilization.
“Generic pharmaceuticals play a critical role in any strategy to hold down health costs,” stated Ralph Neas, president and CEO of GPhA. “As we approach the 30th anniversary of Hatch-Waxman, it is especially important that we preserve and strengthen its legacy by ensuring unimpeded patient access to affordable generic medicines," he said. "We will continue to work with policymakers to ensure any proposed laws and regulations do not undo the framework responsible for decades of more affordable generics and trillions of dollars in savings.”
Through 2013, generic utilization hit an all-time high as 84% of prescriptions dispensed were generic, Neas added. "Efforts to promote generic competition are continuing to bear fruit. Congress passed the Drug Quality and Security Act to establish a nationwide, reliable system for tracking prescription medicine that further safeguards our nation’s prescription drug supply and protects patients," he said. "The law also enhances the ability of regulators to limit risks posed by counterfeit or adulterated products and reassures patients that the generic medicines they receive are secure from the manufacturer all the way to the pharmacy.”
In the states, legislation that would hinder access to biosimilars and interchangeable biosimilars was introduced in 19 states in 2013, blocked in 11, enacted with significant amendments in three states, and enacted with Amgen and Genentech-backed provisions intact in only one state (North Dakota).
Also in 2013, the Supreme Court reaffirmed the constitutionality of patent settlements with consideration and preserved the unprecedented success of the current path for getting generics quickly to patients and consumers.
Looking ahead to 2014, GPhA’s top priority is to protect patient safety and access to affordable medicines by working with stakeholders to ensure that the FDA’s proposed rule on prescription drug labeling reflects sound policy, rather than politics, the association stated. GPhA opposes the FDA proposed rule that would alter the requirements for labels on generic medicines, which the association states would undermine the essential “sameness” of the label between generic and brand drugs mandated by law. It is difficult to overstate the confusion that would be created among health care professionals and consumers when multiple versions of critical safety labeling information makes its way to the marketplace under this rule.
Further, the rule as drafted would lead to billions of dollars in cost increases for government and private payors, and could result in fewer generic drugs coming to market, manufacturers withdrawing from certain markets, drug shortages, the undermining of consumer confidence in affordable generic medicines, and increased drug spending, GPhA noted.
GPhA restated its opposition to any efforts that could hinder timely access to biosimilars and interchangeable biosimilars at the state, federal and international levels. "We will fight against any provisions creating roadblocks to patient access such as limits on substitution, added paperwork for prescribers and pharmacists, or unnecessary mandates for notifying physicians that extend beyond current practice," the association stated. "While there is no ‘one-size-fits-all’ model for states, one can look to the bill enacted in Florida, which sought to create the same substitution model for biosimilars and interchangeable biosimilars as operates so successfully for generic drugs."
And GPhA will continue to promote the value of generics. "Our population is aging and prescription spending continues to weigh on seniors and others, particularly those enrolled in Medicare and/or Medicaid. Generics are one of the few bright spots in the health cost story," the association stated. "Indeed, generics saved the U.S. health system $217 billion in 2012 and $1.2 trillion in the most recent decade, according to the fifth annual 2013 Generic Drug Savings in the U.S. report. Prompt approvals for first generics and prompt resolution of scientific issues are essential to continuation of the benefits reaped by patients and payors alike."
Quality assurance is also a key focus for the generic industry association. "The association stands firmly in support of regulatory goals outlined in the Generic Drug User Fee Act, an effort 100% funded by industry dollars, and is seeking a permanent fix in order to avoid the sequestration of user fees," GPhA stated. GPhA is in constant communication with regulatory partners to ensure that products contain the same active ingredient and are manufactured to identical strength and dosage form as the branded counterpart. Generic drugs also have the same indications of use, dosing and labeling, and provide the same quality, potency, efficacy and safety profile to patients as the brand medicines. These criteria ensure that the generic and the brand have “no clinically meaningful difference and can be safely substituted for each other.”
GPhA also plans to build on last year’s work with Congress, the U.S. Trade Representative and others involved with international trade negotiations such as the Trans Pacific Partnership. These agreements are integral in efforts to open access to global markets and preserve the balance between promoting innovation and competition, GPhA noted. "The association will continue to ensure that barriers to entry for generic products in TPP countries are limited, including mandates of patent term extensions, patent linkage and exclusivity."
And GPhA will be continuing its efforts this year to push for the release and the finalization of the proposed rule to allow for the electronic distribution of prescription information, known as electronic labeling. Under an e-labeling system, prescribers would have immediate access to the most current prescribing information, prescribing errors could be reduced and significant waste would be reduced when millions of pounds of unused outdated paper labels would no longer be disposed each year.